Clinical Trial Update: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of JS001 alone or in combination with pemetrexed and carboplatin for resectable non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• JS001 (PD-1 inhibitor)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Efficacy and Safety | Phase 2 | Status: WITHDRAWN